524 total citations 21 papers, 429 citations indexed
About
Ettinger Ds is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Ettinger Ds has authored 21 papers receiving a total of 429 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Ettinger Ds's work include Lung Cancer Research Studies (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Cancer therapeutics and mechanisms (6 papers). Ettinger Ds is often cited by papers focused on Lung Cancer Research Studies (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Cancer therapeutics and mechanisms (6 papers). Ettinger Ds collaborates with scholars based in United States. Ettinger Ds's co-authors include Mark G. Kris, Donehower Rc, John P. Klein, Baker Rr, Magda Sgagias, David Tritchler, Judith E. Woll, Robert H. Earhart, David Tritchler and K. Stanley and has published in prestigious journals such as PubMed and Munich Personal RePEc Archive (Ludwig Maximilian University of Munich).
In The Last Decade
Ettinger Ds
20 papers
receiving
403 citations
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Ettinger Ds's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ettinger Ds with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ettinger Ds more than expected).
This network shows the impact of papers produced by Ettinger Ds. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ettinger Ds. The network helps show where Ettinger Ds may publish in the future.
Co-authorship network of co-authors of Ettinger Ds
This figure shows the co-authorship network connecting the top 25 collaborators of Ettinger Ds.
A scholar is included among the top collaborators of Ettinger Ds based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Ettinger Ds. Ettinger Ds is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Ds, Ettinger, et al.. (2000). Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group Study (PA586).. PubMed. 6(1). 34–9.3 indexed citations
3.
Ds, Ettinger. (1998). The role of carboplatin in the treatment of small-cell lung cancer.. PubMed. 12(1 Suppl 2). 36–43.20 indexed citations
4.
Ds, Ettinger. (1996). Ifosfamide in the treatment of small cell lung cancer.. PubMed. 23(3 Suppl 6). 2–6.3 indexed citations
5.
Ds, Ettinger. (1995). Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis.. PubMed. 22(4 Suppl 10). 6–18.20 indexed citations
6.
Ds, Ettinger. (1993). Overview of paclitaxel (Taxol) in advanced lung cancer.. PubMed. 20(4 Suppl 3). 46–9.34 indexed citations
7.
Ds, Ettinger. (1993). Taxol in the treatment of lung cancer.. PubMed. 177–9.13 indexed citations
8.
Ds, Ettinger, et al.. (1989). Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin.. PubMed. 16(1 Suppl 3). 31–43.115 indexed citations
9.
Ds, Ettinger, et al.. (1987). Sudden dyspnea occurring 24 hours after mitomycin plus etoposide combination therapy.. PubMed. 71(1). 103–4.
10.
Ds, Ettinger, et al.. (1987). Benign breast disorders: a symptomatic approach.. PubMed. 22(9A). 75–7, 80.3 indexed citations
Ds, Ettinger, et al.. (1985). Phase I study of N-methylformamide in patients with advanced cancer.. PubMed. 69(5). 489–93.16 indexed citations
13.
Tritchler, David, et al.. (1984). Phase II study of PALA, amsacrine, teniposide, and zinostatin in small cell lung carcinoma (EST 2579).. PubMed. 68(9). 1183–4.16 indexed citations
14.
Ds, Ettinger, et al.. (1984). Phase II study of PALA and PCNU in the treatment of non-small cell lung cancer (EST 2580): an Eastern Cooperative Oncology Group study.. PubMed. 68(10). 1297–8.4 indexed citations
15.
Ds, Ettinger, et al.. (1983). Dosimetry of 131I-labeled antiferritin in hepatoma: specific activities in the tumor and liver.. PubMed. 67(7-8). 647–58.54 indexed citations
16.
Stanley, K., et al.. (1982). Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578).. PubMed. 66(6). 1417–9.6 indexed citations
17.
Ds, Ettinger, et al.. (1981). The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast.. PubMed. 152(1). 70–4.13 indexed citations
18.
Ds, Ettinger, et al.. (1979). Important clinical pharmacologic considerations in the use of methadone in cancer patients.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 63(3). 457–9.53 indexed citations
19.
Ds, Ettinger, et al.. (1979). Isotopic immunoglobulin in an integrated multimodal treatment program for a primary liver cancer: a case report.. PubMed. 63(1). 131–4.15 indexed citations
20.
Ds, Ettinger, et al.. (1977). Endodermal sinus tumor. Report of a case with remission following chemotherapy.. PubMed. 49(1 suppl). 53–5.2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.